Stipple Bio launched with a $100 million Series A financing to advance STP-100, an antibody-drug conjugate (ADC) aimed at an undisclosed target, while also building its Pointillist discovery platform. The company expects its lead program to enter the clinic in early 2027. The platform is designed to identify cancer-selective epitopes that may arise from post-translational modifications, protein conformational changes, or mislocalization—rather than simply targets that are overexpressed in tumors. Stipple’s founding teams include Aaron Ring at Fred Hutchinson Cancer Center and Aashish Manglik at the University of California, San Francisco. The fundraising supports both clinical progression and the discovery engine intended to generate additional ADC opportunities. Investors backing the round include RA Capital, a16z Bio+Health, and Nextech Invest, reflecting continued interest in ADC modality innovation and target selectivity. For industry participants, Stipple’s entry adds another early-stage competitor to the ADC field, with the differentiation focused on target biology selection rather than payload changes alone.